Ketamine vs. Antidepressants: A Comprehensive Comparison for Patients

Two Fundamentally Different Approaches

If you are living with depression and researching your options, you have likely come across two very different treatment categories: traditional antidepressants — the SSRIs, SNRIs, and other medications that have been the standard of care for decades — and ketamine therapy, a newer approach that works through an entirely different mechanism.

Understanding how these two approaches compare can help you have more informed conversations with your healthcare provider and make better decisions about your treatment path. This is not about declaring one approach superior to the other. Each has distinct strengths, limitations, and ideal use cases.

How They Work: Mechanisms of Action

Traditional Antidepressants

SSRIs (selective serotonin reuptake inhibitors) like sertraline, fluoxetine, and escitalopram work by increasing the availability of serotonin in the brain. SNRIs (serotonin-norepinephrine reuptake inhibitors) like venlafaxine and duloxetine affect both serotonin and norepinephrine. Other categories — tricyclics, MAOIs, atypical antidepressants — target various combinations of neurotransmitters.

The common thread is the monoamine hypothesis: the idea that depression results from deficiencies in neurotransmitters like serotonin, norepinephrine, or dopamine, and that correcting those deficiencies alleviates symptoms. These medications modulate neurotransmitter levels gradually, which is why they typically take 4 to 8 weeks to produce their full therapeutic effect.

Ketamine

Ketamine works through an entirely different pathway. It primarily acts as an NMDA receptor antagonist, blocking a specific type of glutamate receptor in the brain. This triggers a cascade of downstream effects, including increased release of brain-derived neurotrophic factor (BDNF), rapid formation of new synaptic connections, and restoration of neural pathways that chronic stress and depression have degraded.

This mechanism — often described as promoting neuroplasticity — operates on a much faster timeline. Research published by the National Institute of Mental Health demonstrated antidepressant effects within hours of a single ketamine infusion, a timeline that is unprecedented in psychiatry.

The difference in mechanism is not just academic. It explains why ketamine can help patients who have not responded to traditional antidepressants. If the problem is not primarily a serotonin deficiency but rather a disruption of glutamate signaling and synaptic connectivity, then a medication targeting the glutamate system may succeed where serotonin-based medications have failed.

Speed of Onset

This is one of the most significant differences between the two approaches, and one of the primary reasons ketamine has generated so much clinical interest.

Traditional Antidepressants

SSRIs and SNRIs typically require 4 to 8 weeks to reach full therapeutic effect. During this period, patients may experience side effects before they experience benefits — a particularly difficult reality for someone already struggling with depression. Some patients need to try multiple medications before finding one that works, a process that can stretch to months or even years.

For patients in acute crisis, this timeline can feel agonizing. The most vulnerable period in depression treatment — the weeks when a patient has started medication but is not yet experiencing relief — is also a period of elevated risk.

Ketamine

Ketamine's antidepressant effects can begin within hours to days of the first treatment. In the landmark study by Berman et al. published in Biological Psychiatry, patients with treatment-resistant depression showed significant improvement within 4 hours of a single IV ketamine infusion.

This rapid onset has particular clinical significance for patients experiencing acute suicidal ideation, where the weeks-long timeline of traditional antidepressants is a serious concern. Research published in the American Journal of Psychiatry demonstrated that ketamine can reduce suicidal ideation within 24 hours — a capability no traditional antidepressant can match.

However, the duration of ketamine's effects is also different. While traditional antidepressants provide continuous daily coverage, a single ketamine treatment typically produces benefits lasting days to weeks. Sustained improvement requires a series of initial treatments followed by periodic maintenance sessions.

Effectiveness and Response Rates

Traditional Antidepressants

Traditional antidepressants are effective for a significant portion of the population. The STAR*D trial — the largest study of antidepressant effectiveness ever conducted — found that approximately one-third of patients achieved remission with their first antidepressant. After trying up to four different medications, the cumulative remission rate reached about 67 percent.

These are meaningful numbers. For two-thirds of patients with major depression, traditional antidepressants — potentially after some trial and adjustment — provide sufficient relief. These medications remain the first-line treatment for depression for good reason.

Ketamine

For the remaining one-third of patients — those with treatment-resistant depression who have not responded to at least two adequate antidepressant trials — ketamine offers a compelling alternative. Studies consistently show response rates of 60 to 70 percent in this treatment-resistant population.

To put this in perspective: these are patients for whom traditional antidepressants have already failed, and yet the majority still respond to ketamine. This is a remarkable result that has shifted how the psychiatric community thinks about treatment-resistant depression.

Remission rates — the stricter measure of symptom-free status — are lower with ketamine, typically around 30 to 40 percent after an initial treatment series. But even patients who respond without achieving full remission often experience clinically meaningful improvement in mood, functioning, and quality of life.

Side Effect Profiles

The side effect profiles of traditional antidepressants and ketamine are substantially different, and understanding these differences is important for making an informed choice.

Traditional Antidepressant Side Effects

Common side effects of SSRIs and SNRIs include sexual dysfunction (reduced libido, difficulty achieving orgasm) affecting up to 40 to 60 percent of patients, weight gain (particularly common with certain SSRIs and mirtazapine), gastrointestinal symptoms including nausea, diarrhea, or constipation, insomnia or excessive drowsiness, emotional blunting or feeling "flat," and discontinuation symptoms when stopping the medication, sometimes called "brain zaps."

These side effects are manageable for many patients, but for others they significantly impact quality of life and are a primary reason for discontinuing treatment. Sexual side effects, in particular, are a frequent source of frustration and a common reason patients explore alternative treatments.

Ketamine Side Effects

Ketamine's side effects are generally acute — meaning they occur during and shortly after treatment — rather than ongoing. Common side effects include dissociation (feeling detached from your body or surroundings) during the session, temporary increases in blood pressure and heart rate, nausea or vomiting (usually manageable with anti-nausea medication), dizziness and impaired coordination for several hours after treatment, and fatigue on the day of treatment.

These effects typically resolve within 1 to 2 hours after the session ends. Unlike traditional antidepressants, ketamine does not cause sexual dysfunction, weight gain, or the emotional blunting that many patients find intolerable.

The more significant concern with ketamine is the potential for misuse and dependence, particularly with long-term use. In clinical settings with proper supervision, this risk is managed through controlled dosing, limited access to the medication, and regular clinical assessment. Chronic recreational ketamine use (at much higher doses and frequencies than therapeutic protocols) has been associated with bladder damage and cognitive effects, but these have not been observed at therapeutic doses under medical supervision.

Cost and Accessibility

Traditional Antidepressants

One of the strongest advantages of traditional antidepressants is their accessibility and affordability. Most SSRIs and SNRIs are available as generics, costing as little as $4 to $30 per month with insurance, and many are available through discount pharmacy programs even without insurance.

They are prescribed by primary care physicians, psychiatrists, and many nurse practitioners — providers who are available in virtually every community. No special clinic, monitoring period, or companion is required. You fill a prescription, take a daily pill, and go about your life.

For a condition as prevalent as depression, this accessibility matters enormously. Traditional antidepressants have helped millions of people precisely because they are affordable, widely available, and easy to use.

Ketamine Therapy

Ketamine therapy is significantly more expensive and less accessible. IV infusions typically cost $400 to $800 per session, and most insurance plans do not cover them. An initial treatment course of 6 infusions can total $2,400 to $4,800, with ongoing maintenance adding thousands more annually.

At-home oral ketamine programs through telehealth providers are more affordable — typically $150 to $400 per month — but still represent a significant ongoing expense compared to generic antidepressants.

Spravato (esketamine nasal spray) is the only form of ketamine therapy commonly covered by insurance, but it requires administration at a certified treatment center with a mandatory 2-hour monitoring period, limiting convenience.

Access is also more limited geographically. Ketamine clinics are concentrated in urban and suburban areas, and patients in rural communities may have few or no local options for in-person treatment. Telehealth programs have improved access, but they can only prescribe oral formulations — not IV or intramuscular ketamine.

Who Benefits Most from Each Approach

When Traditional Antidepressants Are the Right Choice

Traditional antidepressants are typically the appropriate first-line treatment for patients experiencing their first episode of major depression, patients who have not yet tried antidepressant medication, patients who need an affordable long-term treatment option, patients who prefer the convenience of a daily oral medication, and patients who respond well to serotonergic or noradrenergic medications.

For the majority of people with depression, starting with a traditional antidepressant — under the guidance of a knowledgeable prescriber — remains the evidence-based standard of care. These medications work well for most people, are well-studied with decades of safety data, and are practical for long-term use.

When Ketamine May Be the Better Option

Ketamine therapy is most appropriate for patients with treatment-resistant depression who have not responded to at least two antidepressant trials, patients in acute crisis or experiencing active suicidal ideation where rapid onset of action is critical, patients who cannot tolerate the side effects of traditional antidepressants (particularly sexual dysfunction or weight gain), and patients who have the financial resources and access to pursue ketamine treatment.

Ketamine is not typically recommended as a first-line treatment for depression. The evidence, cost, and accessibility profile all support trying traditional antidepressants first for most patients.

Combining Approaches

An important point that often gets lost in "ketamine vs. antidepressants" discussions is that the two approaches are not mutually exclusive. Many patients use both.

A common clinical scenario involves continuing a traditional antidepressant while adding ketamine therapy to address residual symptoms or during a particularly difficult period. The ketamine provides rapid relief while the ongoing antidepressant provides baseline maintenance.

Some patients use ketamine therapy as a bridge — a way to achieve rapid stabilization during an acute depressive episode, after which a traditional antidepressant is optimized for long-term management. Others find that the neuroplasticity window created by ketamine allows them to respond to antidepressants that had previously been ineffective.

There are some medication interactions to be aware of. Benzodiazepines may reduce the effectiveness of ketamine, and your provider will give you specific guidance about medication timing around ketamine sessions. Lamotrigine has also been studied for potential interactions, though the clinical significance remains debated.

Always discuss your full medication regimen with your ketamine provider. They need the complete picture to treat you safely and effectively. For more on drug interactions, see our guide on ketamine with other medications.

The Bigger Picture

The emergence of ketamine therapy has fundamentally changed the treatment landscape for depression. For decades, patients who did not respond to traditional antidepressants had limited options. Ketamine has provided a genuinely effective alternative for a population that was previously underserved.

At the same time, traditional antidepressants remain indispensable. They are the foundation of depression treatment for the majority of patients, and their combination of effectiveness, safety, affordability, and convenience is unmatched by any other treatment currently available.

The most useful way to think about these two approaches is not as competitors but as complementary tools in a broader treatment toolkit. The right choice depends on your clinical history, your response to previous treatments, your financial situation, and your personal preferences. Work closely with a knowledgeable provider who understands both approaches and can help you navigate the options with your specific situation in mind. If you are considering ketamine, our complete guide to ketamine therapy covers everything you need to know to get started.

References

• A Single Dose of Ketamine Produces Rapid Antidepressant Effects — Landmark NIMH-funded study demonstrating rapid antidepressant effects of ketamine
• STAR*D Study: Sequenced Treatment Alternatives to Relieve Depression — The largest study of antidepressant effectiveness showing response and remission rates across treatment steps
• Ketamine and Rapid Reduction of Suicidal Ideation — Research on ketamine's ability to reduce suicidal thoughts within 24 hours
• Glutamate and GABA Systems as Targets for Novel Antidepressant Drugs — NIH review of the glutamate hypothesis of depression and ketamine's mechanism of action
• NIMH: Mental Health Medications — NIMH resource comparing medication classes for mental health conditions
• Mayo Clinic: SSRIs and Depression — Mayo Clinic overview of SSRI antidepressants, their benefits, and limitations